Fluconazole in the treatment of mycotic oropharyngeal stomatitis and esophagitis in neutropenic cancer patients.
The efficacy and safety of fluconazole, a new triazole antifungal agent, was evaluated in 24 patients with neutropenia due to cytotoxic anticancer chemotherapy with polyfactorial immunodepression. Twenty of 23 patients benefited from treatment, and except for 1 patient with mild abdominal discomfort the drug was well tolerated. Mycological eradication appeared in 17 from 23 evaluable patients, superinfection in 1 case and persistence could be evaluated in 5 cases. Candida albicans, C. crusei and C. pseudotropicalis together with Torulopsis sp. were the most frequently isolated organisms from pharyngeal and esophageal mucosa in treated patients with oropharyngeal and esophageal mycosis.
Krcméry
V
V
Department of Clinical Oncology, Postgraduate Medical Institute, Bratislava, CSFR.
Koza
I
I
Hornikova
M
M
Fuchsberger
P
P
Spanik
S
S
Mardiak
J
J
Sufliarsky
J
J
Blahova
M
M
Savko
V
V
Migom
C
C
D000284:Administration, Oral; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects; D002180:Candidiasis, Oral / Q000188:drug therapy*; D004341:Drug Evaluation; D004941:Esophagitis / Q000188:drug therapy*; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D009181:Mycoses / Q000188:drug therapy*; D009369:Neoplasms / Q000150:complications; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications*; D010612:Pharyngitis / Q000188:drug therapy*
D000970:Antineoplastic Agents; D015725:Fluconazole